United Therapeutics (NASDAQ:UTHR) CEO Sells $5,079,270.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $534.66, for a total value of $5,079,270.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $173,466,694.38. This represents a 2.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Up 1.9%

Shares of NASDAQ UTHR traded up $10.03 during trading hours on Monday, hitting $543.15. The company had a trading volume of 495,524 shares, compared to its average volume of 556,959. United Therapeutics Corporation has a 1-year low of $409.07 and a 1-year high of $609.35. The firm’s 50 day moving average is $513.64 and its 200-day moving average is $540.06. The stock has a market capitalization of $23.30 billion, a P/E ratio of 19.43, a price-to-earnings-growth ratio of 3.81 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the company earned $6.41 earnings per share. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.40 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. UBS Group set a $725.00 price objective on shares of United Therapeutics in a research report on Monday. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Morgan Stanley upped their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. The Goldman Sachs Group reiterated a “sell” rating and issued a $368.00 target price on shares of United Therapeutics in a research note on Thursday. Finally, Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $650.00.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in UTHR. Callan Family Office LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth about $1,217,000. Andra AP fonden grew its stake in United Therapeutics by 33.5% in the 2nd quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock valued at $18,912,000 after buying an additional 8,760 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in United Therapeutics in the 2nd quarter valued at about $3,359,000. Partners Capital Investment Group LLP acquired a new position in United Therapeutics in the 2nd quarter valued at about $1,691,000. Finally, Palo Alto Investors LP bought a new position in United Therapeutics in the 2nd quarter valued at about $33,911,514. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.